PROFNAIT

Development of a prophylactic treatment for the prevention of fetal/neonatal alloimmune thrombocytopenia (FNAIT)

 Coordinatore PROPHYLIX PHARMA AS 

 Organization address address: SYKEHUSVEGEN 23 FORSKNINGSPARKEN
city: TROMSO
postcode: 9019

contact info
Titolo: Dr.
Nome: Søren
Cognome: Dahl
Email: send email
Telefono: +45 4260 5260

 Nazionalità Coordinatore Norway [NO]
 Totale costo 7˙837˙467 €
 EC contributo 5˙986˙000 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-08-01   -   2018-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    PROPHYLIX PHARMA AS

 Organization address address: SYKEHUSVEGEN 23 FORSKNINGSPARKEN
city: TROMSO
postcode: 9019

contact info
Titolo: Dr.
Nome: Søren
Cognome: Dahl
Email: send email
Telefono: +45 4260 5260

NO (TROMSO) coordinator 2˙719˙082.60
2    LARIX AS

 Organization address address: TEMPOVEJ 44 - 1st floor
city: BALLERUP
postcode: 2750

contact info
Titolo: Mrs.
Nome: Mette
Cognome: Ravn
Email: send email
Telefono: 4530128426

DK (BALLERUP) participant 709˙737.24
3    UNIVERSITETSSYKEHUSET NORD-NORGE HF

 Organization address address: SYKEHUSVEIEN 38
city: TROMSO
postcode: 9019

contact info
Titolo: Dr.
Nome: Mira Grujic
Cognome: Arsenovic
Email: send email
Telefono: 4777626299

NO (TROMSO) participant 585˙193.06
4    DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH

 Organization address address: FRIEDRICH EBERT STRASSE 107
city: MANNHEIM
postcode: 68167

contact info
Titolo: Dr.
Nome: Christof
Cognome: Geisen
Email: send email
Telefono: +49 174 3377 345

DE (MANNHEIM) participant 553˙903.20
5    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Mr.
Nome: Michael
Cognome: Prestele
Email: send email
Telefono: 498912000000
Fax: 498912000000

DE (MUENCHEN) participant 517˙905.70
6    STOCKHOLMS LAENS LANDSTING

 Organization address address: Hantverkargatan 45
city: STOCKHOLM
postcode: 104 22

contact info
Titolo: Dr.
Nome: Agneta
Cognome: Taune Wikman
Email: send email
Telefono: 46736204601
Fax: 46858589410

SE (STOCKHOLM) participant 287˙401.44
7    OSLO UNIVERSITETSSYKEHUS HF

 Organization address address: FORSKNINGSVEIEN 2B
city: OSLO
postcode: 373

contact info
Titolo: Mr.
Nome: Helge
Cognome: Haukås
Email: send email
Telefono: 4723071208

NO (OSLO) participant 237˙439.22
8    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Prof.
Nome: Martin L.
Cognome: Olsson
Email: send email
Telefono: +46 46 2223207
Fax: +46 46 176006

SE (LUND) participant 165˙613.26
9    UNIVERSITETET I TROMSOE

 Organization address address: Hansine Hansens veg 14
city: TROMSO
postcode: 9037

contact info
Titolo: Prof.
Nome: Anne
Cognome: Husebekk
Email: send email
Telefono: +47 48141286

NO (TROMSO) participant 108˙326.40
10    REGION NORDJYLLAND (NORTH DENMARK REGION)

 Organization address address: Niels Bohrs Vej 30
city: AALBORG
postcode: 9220

contact info
Titolo: Prof.
Nome: Kim
Cognome: Varming
Email: send email
Telefono: +45 99 32 11 25

DK (AALBORG) participant 78˙389.98
11    SKANE LANS LANDSTING

 Organization address city: KRISTIANSTAD
postcode: 291 89

contact info
Titolo: Prof.
Nome: Kjell
Cognome: Salvesen
Email: send email
Telefono: 4645172550

SE (KRISTIANSTAD) participant 18˙900.00
12    BIOTEST AG

 Organization address address: LANDSTEINER STRASSE 5
city: DREIEICH
postcode: 63303

contact info
Titolo: Dr.
Nome: Sebastian
Cognome: Breuer
Email: send email
Telefono: +49 6103 801 262

DE (DREIEICH) participant 4˙107.09

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

prophylactic    fetus    platelet    anti    newborns    immune    antigen    tromplate    reg    hpa    treatment    fnait    fetal    screening    pregnancies    fetuses    subsequent    igg    antibodies    pregnant    develops    immunisation    prevent    rare    mother   

 Obiettivo del progetto (Objective)

'Objective--The project aims to develop an anti HPA-1a immunoglobulin (IgG), Tromplate® that can prevent post delivery immunisation of the mother against the Human Platelet Antigen-1a (HPA-1a). This prophylactic treatment will prevent Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) in the fetus/newborn in subsequent pregnancies. FNAIT--FNAIT is a rare but potentially serious condition which affects about 4,000 fetuses and newborns a year in EU-27 and which may result in severe bleeding, intracranial hemorrhage, fetal death or lifelong disability. FNAIT may develop when the mother and the fetus have different platelet surface antigens, most commonly HPA-1a. Transferral of HPA-1a antigen from the fetus may cause immunisation of the mother and the anti-HPA-1a antibodies she develops may in turn destroy the platelets of subsequent HPA-1a positive fetuses/newborns and cause FNAIT. Today, no good treatment of FNAIT exists. Rationale--Previously, it was believed that the pregnant woman develops antibodies early in the first pregnancy with the implication that FNAIT could not be prevented. However, a study conducted by the applicants of more than 100,000 pregnancies revealed that HPA-1a antibody formation most often takes place in association with or after delivery. Therefore, anti-HPA-1a IgG given to the mother shortly after birth should prevent her immune system from generating harmful anti-HPA-1a antibodies. This concept is analogous to the use of anti(D) for Rhesus D prophylaxis. Activities--The project elements: manufacturing of Tromplate® using the process for producing anti(D); screening for HPA-1a negative and pregnant women and clinical Phase II/III studies investigating the efficacy and safety of Tromplate®. Relevance to the work program−The prophylactic Tromplate® treatment has obtained orphan drug status in Europe. FNAIT represents a significant health care expense for the society and a great burden for the affected children and their families.'

Introduzione (Teaser)

Immunoglobulins are emerging as a safe and efficacious approach for preventing female immunisation by an antigen from her foetus. European scientists are screening such a strategy for a rare immune-mediated condition.

Altri progetti dello stesso programma (FP7-HEALTH)

ANTIGONE (2011)

ANTIcipating the Global Onset of Novel Epidemics

Read More  

MEDIA (2011)

The MEtabolic Road to DIAstolic Heart Failure

Read More  

TALOS (2008)

Targeting LRP5 to Increase Bone Formation in Osteoporosis

Read More